MYM Nutraceuticals Inc. (CSE:MYM) and Sherbrooke College (CEGEP) are pleased to announce the signing of a partnership agreement to develop a training program for MYM’s employees assigned to the production of cannabis. The educational curriculum will be expanded and offered as a diploma (AEC) program as part of the Sherbrooke College (CEGEP) course offerings.

Under the terms of this agreement, MYM retains the services of the Sherbrooke College (CEGEP) Continuing Education Center to develop and deliver tailor-made training and learning programs leading to a diploma (AEC) in the fields of production, agricultural management and associated laboratory techniques specific to the production of cannabis. The agreement is valid for a five-year period, beginning July 1, 2018. Upon construction of the Company’s production facility in Weedon, Québec being completed, the Company anticipates using such facility to provide certain physical and technical resources to the Continuing Education Center.


”We are pleased to be able to rely on the Sherbrooke College (CEGEP) Continuing Education Center to develop customized training for our future employees, including programs leading to a diploma,” said Rob Gietl, CEO of MYM. “The signing of this agreement with Sherbrooke College (CEGEP) satisfies the Company’s desire to develop its workforce by calling on the area’s educational resources and aiding in the development of such resources.”

Sherbrooke College (CEGEP) Executive Director, Ms. Marie-France Bélanger, points out that this partnership is very much aligned with the learning institution’s core purpose: “In joining this important economic development project in the MRC du Haut-Saint-François, we intend to contribute by bringing in our training expertise. This approach is completely in line with our mission to meet the needs of our region and support businesses in their growth projects.”

Mr. Éric Fernet, Director of the Sherbrooke College (CEGEP) Continuing Education Center and Businesses Services, adds that this agreement follows the direction taken by the Continuing Education Center: “Considering the current pressing needs for labor, we are focusing more on offering onsite training services to meet the needs of both individuals and businesses. We thus prefer agile and effective training methods for tailor-made or turnkey solutions.”

MYM recently announced the start of construction for its Weedon project, which is expected to be a 1.5 million square foot cannabis greenhouse located in Weedon, Québec. The project also intends to begin construction on a multifunctional CannaCentre which will host a research facility, staff training center, museum, hotel, and restaurant. A report by Deloitte estimates that the Weedon project could bring investment of $200 million and could create 400 jobs for the region.

About Sherbrooke College (CEGEP)

Sherbrooke College (CEGEP) offers 24 technical programs, nine pre-university programs, as well as a wide range of continuous learning programs and services to businesses. Relying on its niche strengths, it has also engaged in research activities, as well as in international cooperation and regional projects. On a nearly ten-hectare campus, it welcomes some 6,000 students annually in its regular learning programs offered in six pavilions. It has a residence for students, as well as a general learning service point in Asbestos, and another specializing in agriculture in Coaticook. The institution is the largest in the province outside Montréal and Québec City, and ranks among the Eastern Township’s most important employers with a staff of more than 800 people.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Québec that when completed is anticipated to have over 1.8 million square feet of production space. MYM is also a shareholder in a production project (Northern Rivers Project) in New South Wales, Australia that is expected to have 1.2-million-square feet of production space. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

On Behalf of The Board
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mym.ca

Keep up to date with MYM on our social media channels:

Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

This release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws, including statements regarding the provision of physical and technical support through the CannaCentre to Sherbrook College’s Continuing Education Center, the successful completion of the Weedon facility and CannaCentre, the anticipated 1.5 million square feet of production space in the Weedon facility, the anticipated combined production space of 1.8 million square feet for the two production projects in Quebec, the anticipated 1.2 million square feet of production space in the Northern Rivers Project, the investment of $200 million and the creation of 400 jobs in the Weedon region as a result of the Weedon Project.  Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends,” “anticipates,” “it is expected,” or variations of such words and phrases, or statements that certain actions, events or results “may,” “could,” “should,” or “would” occur. Forward-looking statements are based on certain material assumptions and analyses made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that MYM’s subsidiary will acquire a Health Canada license to cultivate cannabis in Weedon, that the project will be completed as planned, with 1.5 million square feet of greenhouse space as well as the successful completion and operation of the  multipurpose CannaCentre with museum, auditorium, cafeteria, school, restaurant, bookstore, luxury hotel, clinic and cannabis research and innovation centre, that the terms and conditions of the Company’s partnership agreement with Sherbrooke College will be fulfilled, that the Northern Rivers Project will be completed as planned, including the construction and operation of 1.2 million square feet of production space. Although the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect, and the forward-looking statements in this release are subject to numerous risks, uncertainties and other factors that may cause future results to differ materially from those expressed or implied in such forward-looking statements.  Such risk factors may include, among others, MYM’s subsidiary not obtaining a Health Canada license to cultivate cannabis at the facility, and not building, or being able to build due to a lack of funding or inability to obtain the proper permits and allowances, all of the various buildings comprising the Weedon facility, the Northern Rivers Project will not be successfully built as planned, the CannaCentre will not be built to adequately assist in the development ofSherbrooke College’s Continuing Education Center’s programs and the terms and conditions of the Company’s partnership agreement with Sherbrooke will not be fulfilled or such agreement will be terminated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that is incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Investor Relations
Terry Brown
+1-855-696-2261
terry.brown@mym.ca

Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation. 

Source: www.newswire.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less